15 completed, 15 terminated, 11 recruiting, 7 active not recruiting. 56 Phase 2, 15 Phase 1, 11 Phase 3.
Follow Epileptic Syndromes: new trials by email Literature Review of Epileptic Syndromes trials Research Report on Epileptic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders Glycerol Phenylbutyrate - SLC6A1 | Phase 2 | Recruiting | Scripps Translational Science Institute | 20 | 2026-10-01 | 2026-09-29 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-11-12 |
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-11-02 |
| Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2025-11-06 | 2026-04-07 |
| A Study to Prevent Infantile Spasms Relapse Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2025-05-05 | 2025-05-08 |
| Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy Ferumoxytol - Epilepsy, Temporal Lobe | Phase 2 | Recruiting | University of Alberta | 50 | 2025-05-01 | 2026-05-08 |
| A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures NPT 2042, Placebo - Epilepsy, Generalized, Epilepsy, Absence | Phase 2 | Completed | NeuroPro Therapeutics, Inc. | 14 | 2025-03-11 | 2026-09-28 |
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
| A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) NRTX-1001 - Epilepsy, Temporal Lobe | Phase 1 / Phase 2 | Recruiting | Neurona Therapeutics | 10 | 2024-11-14 | 2026-01-07 |
| Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-10-24 | 2026-07-13 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy | Phase 1 / Phase 2 | Recruiting | UniQure Biopharma B.V. | 12 | 2024-06-12 | 2026-08-24 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Encoded Therapeutics | 113 | 2024-05-14 | 2026-10-23 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 5 | 2024-05-09 | 2026-06-08 |
| Cortical Excitability in West Syndrome Using Transcranial Magnetic Stimulation ACTH/Oral Steroids - West Syndrome | Phase 2 / Phase 3 | Unknown | All India Institute of Medical Sciences | 40 | 2024-03-01 | 2024-03-04 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 4 | 2024-02-28 | 2025-11-14 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-02-21 | 2026-04-09 |
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
Showing 20 of 56. Sign in to see all of them.
Epilepsies, Myoclonic (18) · Spasms, Infantile (16) · Epilepsy (14) · Lennox Gastaut Syndrome (9) · Seizures (8) · Epilepsy, Absence (7) · Epilepsy, Temporal Lobe (4) · CDKL5 deficiency disorder (3) · Leigh Disease (3) · MELAS Syndrome (3) · MERRF Syndrome (3) · Mitochondrial Diseases (3) · Mitochondrial Encephalomyopathies (3) · Myoclonic Epilepsies, Progressive (3) · Myoclonic Epilepsy, Juvenile (3)
Brain Diseases (55) · Central Nervous System Diseases (55) · Nervous System Diseases (55) · Epilepsy, Generalized (46) · Epilepsy (42) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Genetic Diseases, Inborn (16) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (13) · Neurologic Manifestations (12) · Epilepsies, Myoclonic (11) · Heredodegenerative Disorders, Nervous System (7) · Neurodegenerative Diseases (7) · Pathologic Processes (6)
Cannabidiol (5) · Adrenocorticotropic Hormone (2) · Cysteamine (2) · Diet, Ketogenic (2) · Fenfluramine (2) · Topiramate (2) · ganaxolone (2) · Acetazolamide (1) · Buspirone (1) · Carbamazepine (1) · Diazepam (1) · Diet Therapy (1) · Famotidine (1) · Ferrosoferric Oxide (1) · Flunarizine (1)
All India Institute of Medical Sciences (3) · Encoded Therapeutics (3) · Lady Hardinge Medical College (3) · n-Lorem Foundation (3) · Amgen (2) · Gillette Children's Specialty Healthcare (2) · Jazz Pharmaceuticals (2) · Longboard Pharmaceuticals (2) · Marinus Pharmaceuticals (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Radius Pharmaceuticals, Inc. (2) · Stoke Therapeutics, Inc (2) · Takeda (2) · Alexander Rotenberg (1) · Berge Minassian (1)
United States (38) · Australia (8) · India (7) · Canada (6) · United Kingdom (5) · Poland (4) · Spain (4) · France (3) · Italy (3) · Portugal (3) · Belgium (2) · China (2) · Finland (2) · Germany (2) · Israel (2)
Ahmed Elkashef, MD (2) · Ann Dandurand, MD (2) · Beverly S Wical, MD (2) · Dennis J Dlugos, MD (2) · Salvador Rico, M.D., Ph.D (2) · Suvasini Sharma, MD, DM (2) · William H Theodore, M.D. (2) · Alexander Rotenberg, MD, PhD (1) · Berge Minassian, MD (1) · Daniel Shrey, MD (1) · Dipti Kapoor, MD (1) · Donald Gross, MD (1) · Eduardo Dunayevich, MD (1)
PMID 41780062, PMID 21920781, PMID 30146701, PMID 33575989, PMID 33834913, PMID 35841234, PMID 40840039, PMID 42663529
2018 (2), 2014 (1), 2016 (1), 2023 (1), K12TR004410 (1), U54NS078059 (1), UH3NS109557 (1)